View Older Stories View More Recent Stories

Jul 24, 2025 05:23AM Citi Starts Sarepta Therapeutics (SRPT) at Sell

Jul 23, 2025 09:57AM Freedom Broker Downgrades Sarepta Therapeutics (SRPT) to Hold

Jul 23, 2025 06:05AM BofA Securities Downgrades Sarepta Therapeutics (SRPT) to Underperform

Jul 22, 2025 05:29PM SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Jul 22, 2025 04:00PM ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT

Jul 22, 2025 03:36PM SRPT CLASS NOTICE: BFA Law Reminds Sarepta Therapeutics, Inc. Investors of the Pending Securities Fraud Class Action and August 25 Court Deadline

Jul 22, 2025 10:58AM TD Cowen Reiterates Hold Rating on Sarepta Therapeutics (SRPT)

Jul 22, 2025 10:07AM Sarepta Therapeutics (SRPT) Stock PT Cut in Half at BMO Capital

Jul 22, 2025 09:30AM Sarepta Therapeutics (SRPT) PT Lowered at Piper Sandler After a 'Voluntary Pause Of Elevidys'

Jul 22, 2025 06:37AM H.C. Wainwright Reiterates Sell Rating and $0 Price Target on Sarepta Therapeutics (SRPT)

Jul 22, 2025 05:20AM SRPT INVESTOR ALERT: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

Jul 22, 2025 03:52AM Barclays Downgrades Sarepta Therapeutics (SRPT) to Equalweight

Jul 21, 2025 08:51PM Sarepta pauses U.S. shipments of Duchenne therapy ELEVIDYS

Jul 21, 2025 07:57PM Sarepta Therapeutics (SRPT) Announces Voluntary Pause Of Elevidys Shipments In US

Jul 21, 2025 02:08PM ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT

Jul 21, 2025 09:09AM Sarepta Therapeutics (SRPT) PT Lowered to $18 at Piper Sandler

Jul 21, 2025 07:55AM Cantor Fitzgerald Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)

Jul 21, 2025 07:36AM SRPT DEADLINE REMINDER: Sarepta Therapeutics, Inc. Investors with Losses are Reminded to Contact BFA Law by the Upcoming August 25 Securities Fraud Deadline

Jul 21, 2025 07:04AM Guggenheim Reiterates Buy Rating on Sarepta Therapeutics (SRPT)

Jul 21, 2025 06:55AM TD Cowen Reiterates Hold Rating on Sarepta Therapeutics (SRPT)

Jul 21, 2025 06:43AM H.C. Wainwright cuts Sarepta (SRPT) price target to $0, reiterates Sell rating

Jul 21, 2025 06:03AM BofA Securities Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)

Jul 21, 2025 05:50AM Wells Fargo Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)

Jul 21, 2025 05:43AM Sarepta Therapeutics (SRPT) PT Lowered to $20 at JPMorgan

Jul 21, 2025 05:23AM Sarepta Therapeutics (SRPT) options active amid large share price sell off

Jul 21, 2025 05:05AM BMO Capital Reiterates Market Perform Rating on Sarepta Therapeutics (SRPT)

Jul 21, 2025 05:04AM William Blair Reiterates Market Perform Rating on Sarepta Therapeutics (SRPT)

Jul 21, 2025 04:33AM Mizuho Downgrades Sarepta Therapeutics (SRPT) to Neutral

Jul 21, 2025 03:23AM Leerink Partners Downgrades Sarepta Therapeutics (SRPT) to Market Perform

Jul 21, 2025 03:21AM Deutsche Bank Downgrades Sarepta Therapeutics (SRPT) to Sell

Jul 19, 2025 02:16PM ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT

Jul 18, 2025 08:10PM Sarepta receives FDA request to halt ELEVIDYS shipments for some patients

Jul 18, 2025 02:19PM Baird Downgrades Sarepta Therapeutics (SRPT) to Neutral, 'Transparency Issues and Elevidys Uncertainty'

Jul 18, 2025 02:10PM ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT

Jul 18, 2025 12:53PM FDA to Request Sarepta (SRPT) to Voluntarily Stop All Shipments of Elevidys - Reuters

Jul 18, 2025 12:09PM FDA Investigating Whether Sarepta's (SRPT) Elevidys Should Stay On The Market - Bloomberg

Jul 18, 2025 12:04PM Sarepta Therapeutics (SRPT) PT Lowered to $50 at BMO Capital Following Mangement Call

Jul 18, 2025 11:45AM Needham Downgrades Sarepta Therapeutics (SRPT) to Hold

Jul 18, 2025 11:45AM SRPT Investors Have the Opportunity to Lead the Sarepta Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Jul 18, 2025 10:46AM Sarepta Therapeutics (SRPT) CEO: did not disclose patient death on June 16 call as "It was neither material nor central to the topics at hand" - Conference Call

Jul 18, 2025 09:42AM Sarepta Therapeutics (SRPT) PT Lowered to $20 at BofA Securities, 'Safety reports could limit uptake of SRPT’s gene therapies'

Jul 18, 2025 09:33AM Morgan Stanley Reiterates Equalweight Rating on Sarepta Therapeutics (SRPT)

Jul 18, 2025 08:59AM Goldman Sachs Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)

Jul 18, 2025 08:58AM William Blair on Sarepta Therapeutics (SRPT): 'we continue to view the stock’s near-term upside potential as limited'

Jul 18, 2025 08:55AM Leerink Partners Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)

Jul 18, 2025 06:54AM Sarepta shares tumble after report of patient death in early-stage trial

Jul 18, 2025 05:44AM Sarepta Therapeutics (SRPT) PT Raised to $28 at TD Cowen

Jul 17, 2025 04:00PM SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Jul 17, 2025 08:33AM Cantor Fitzgerald Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)

Jul 17, 2025 07:11AM Needham Reiterates Buy Rating on Sarepta Therapeutics (SRPT)

View More Recent Stories View Older Stories